DAXOR CORP

DAXOR CORP, trading as DXR, manufactures and markets precision X-ray-based blood volume analyzers and calibration services that serve hospitals, clinical laboratories, biopharma trials, and research institutions that rely on accurate plasma volume and red cell mass measurements to manage treatment efficacy and safety; operating within the medical instruments SIC 3827 niche, the company blends proprietary densitometry hardware with value-added service programs and data management support to help pulmonary, cardiac, and renal specialists interpret complex hemodynamic conditions while complying with FDA medical device requirements and the SEC’s ongoing disclosure regime, so investors should weigh the risks tied to health-care reimbursement shifts, regulatory approvals, and the liquidity constraints common to smaller cap issuers; CIK 27367 anchors those disclosures, and although the most recent filing detail is not currently available, the company’s presence in a regulated medical device ecosystem underscores the need for vigilant monitoring—view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025